Kalbe has recorded revenue of IDR 7.00 trillion or an increase of 15.3% compared to the revenue of IDR 6.07 trillion in 2006. Kalbe’s growth in 2007 had exceeded the growth of national pharmaceutical industry.
The details of each Division’s performance are as follows:
- Consumer Health DivisionThis Division consists of 3 sub-divisions i.e. Nutritional, Over-the-Counter and Energy Drink. In 2007, this Division recorded revenue of IDR 3.46 trillion or increase of 9.3% compared to IDR 3.16 trillion recorded in 2006, with the largest contribution and highest growth from Nutritional.
- Prescription Pharmaceutical DivisionThis Division contributed 25.8% to the total consolidated sales in 2007 and recorded revenue of IDR 1.81 trillion or 24.0% higher than IDR 1.46 trillion in 2006. Kalbe had successfully integrated its Marketing Department in 2006 and the benefit had been realized in 2007.
- Distribution and Packaging DivisionThis Division contributed 24.9% to total consolidated revenue and recorded third parties’ revenue of IDR 1.74 trillion in 2007, 20.0% higher than recorded revenue of IDR 1.45 trillion in 2006. This good growth was due to the new principals acquired.
Kalbe recorded gross profit of IDR 3.55 trillion or 14.6% higher compared to IDR 3.10 trillion in 2006. Gross profit margin decreased from 51.0% of Net Sales last year to 50.7% of Net Sales this year. This is due to the price increase of raw materials and changes of Kalbe’s business portfolio.
Operating expenses in 2007 was IDR 2.42 trillion or increased by 19.5% compared to IDR 2.03 trillion in 2006. The increase in operating expenses was due to increase in marketing activities to maintain and increase market share of Kalbe’s product, increase in transportation and delivery costs in Distribution Division and increase in research and development expenses. Kalbe has always made efforts to optimize its expenses in line with its sales growth.
Operating Profit reached IDR 1.13 trillion which was 5.4% higher than IDR 1.07 trillion recorded in 2006. Operating profit ratio decreased from 17.6% of Net Sales in 2006 to become 16.1% of Net Sales this year.
The Company posted net profit of IDR 706 billion or 4.3% higher than IDR 677 billion recorded in 2006.
With regards to the share buy-back programs, up to March 27, 2008, Kalbe has bought back 327.975.500 shares with total transaction of IDR 386.090.222.969.
This information will be available on Kalbe’s website at www.kalbe.co.id or for further information please contact:
Vidjongtius / Corporate Secretary
PT Kalbe Farma Tbk.
KALBE Building
Let. Jend. Suprapto Kav. 4
Cempaka Putih – Jakarta
Indonesia Phone : (6221) 428-73688
Faximile: (6221) 428-73678
Email : vidjongtius@kalbe.co.id
